Bortenat (bortezomib) for Injection

Bortenat is a brand-name prescription drug that’s FDA-approved to treat• Mantle cell lymphoma in patients who have received at least one other type of treatment. & • Multiple myeloma. Brand Name: Bortenat (bortezomib) for Injection For subcutaneous or intravenous use Initial U.S. Approval: 2003

Home | (bortezomib) for Injection

Bortenat (bortezomib) for Injection In India and Overseas
Bortenat (bortezomib) for Injection

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Overseas Patient/ Export inquires.

Call / WhatsApp Number
+91 9643240915 (Mr. Yashpal Singh)
+91 9289711087 (Ms. Sana Sadyar)

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

Bortenat (bortezomib) for Injection

Bortezomib is approved to treat: • Mantle cell lymphoma in patients who have received at least one other type of treatment. & • Multiple myeloma. Bortezomib is also being studied in the treatment of other types of cancer.

Bortenat is a proteasome inhibitor indicated for:
• treatment of patients with multiple myeloma
• treatment of patients with mantle cell lymphoma

Bortezomib, A drug used to treat adults with multiple myeloma or mantle cell lymphoma. It is also being studied in the treatment of other types of cancer. Bortezomib blocks the action of enzymes called proteasomes, which may help keep cancer cells from growing and may kill them. It is a type of proteasome inhibitor. Also called PS-341 and Velcade. Bortezomib is approved to treat adults with: • Mantle cell lymphoma in patients who have received at least one other type of treatment. & • Multiple myeloma. Bortezomib is also being studied in the treatment of other types of cancer.

Drug (Brand / Generic): Bortenat / bortezomib
Current Indications: multiple myeloma and mantle cell lymphoma
Marketed by:: Natco Pharma Ltd.
Approval Date: 2003

Available as (Form & Strength): • Single-use vial contains 3.5 mg of bortezomib as lyophilized powder. Bortenat (bortezomib) for Injection is supplied as individually cartoned 10 mL vials containing 3.5 mg of bortezomib as a white to off-white cake or powder.

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.